Study Title

novartis

A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer

Study Details

Description:

The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other serious adverse reaction(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.

Sponsor:

Novartis

Contacts:

Novartis Pharmaceuticals

novartis.email@novartis.com

1-888-669-6682

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Not yet provided. Contact Novartis Pharmaceuticals for more information.

1-888-669-6682

novartis.email@novartis.com

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468